MARKET

SYRS

SYRS

Syros Pharmaceut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7774
+0.0078
+1.01%
After Hours: 0.8045 +0.0271 +3.49% 19:56 05/17 EDT
OPEN
0.8000
PREV CLOSE
0.7696
HIGH
0.8160
LOW
0.7162
VOLUME
731.06K
TURNOVER
0
52 WEEK HIGH
7.03
52 WEEK LOW
0.7162
MARKET CAP
48.26M
P/E (TTM)
-0.5628
1D
5D
1M
3M
1Y
5Y
10 Biggest Price Target Changes For Tuesday
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday.
Benzinga · 12h ago
Alliance Global Adjusts Price Target on Syros Pharmaceuticals to $10 From $14, Reiterates Buy Rating
MT Newswires · 19h ago
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Benzinga · 1d ago
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 16.67% and 20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share $0.40
reuters.com · 1d ago
Syros Pharmaceuticals: Q1 Earnings Insights
  Syros Pharmaceuticals (NASDAQ:SYRS) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 1d ago
Syros Pharmaceuticals Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $5.47M Beat $4.92M Estimate
Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 14.89 percent. This is a 73.91 percent decrease over losses of $(0.23) per share
Benzinga · 1d ago
Syros Pharmaceuticals GAAP EPS of -$0.40 beats by $0.07, revenue of $5.47M beats by $0.55M
Syros Pharmaceuticals press release (NASDAQ:SYRS): Q1 GAAP EPS of -$0.40 beats by $0.07. Revenue of $5.47M (+13.3% Y/Y) beats by $0.55M. Cash, cash equivalents and marketable securities as of March
Seekingalpha · 1d ago
More
No Data
Learn about the latest financial forecast of SYRS. Analyze the recent business situations of Syros Pharmaceut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

12.50%Strong Buy
87.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SYRS stock price target is 14.71 with a high estimate of 23.00 and a low estimate of 9.00.
High23.00
Average14.71
Low9.00
Current 0.7774
EPS
Actual
Estimate
-0.38-0.28-0.19-0.09
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 115
Institutional Holdings: 53.42M
% Owned: 86.05%
Shares Outstanding: 62.08M
TypeInstitutionsShares
Increased
31
2.73M
New
11
495.27K
Decreased
32
1.34M
Sold Out
22
837.96K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.35%
Pharmaceuticals & Medical Research
+1.51%
Key Executives
Non-Executive Chairman/Independent Director
Peter Wirth
President/Chief Executive Officer/Director
Nancy Simonian
Chief Financial Officer
Jason Haas
Chief Scientific Officer
Eric Olson
Other
Conley Chee
Other
David Roth
Other
Kristin Stephens
Director
Richard Young
Independent Director
Srinivas Akkaraju
Independent Director
Mark Alles
Independent Director
Deborah Dunsire
Independent Director
S. Gail Eckhardt
Independent Director
Marsha Fanucci
Independent Director
Amir Nashat
Independent Director
Phillip Sharp
No Data
No Data
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefending the power of small molecules to control the expression of genes. The Company is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicine. Its lead product candidates include SY-1425, SY-2101 and SY-5609. Its SY-1425, is a selective retinoic acid receptor alpha (RARα) that is being evaluated in combination with azacytidine used to treat acute myeloid leukemia (AML). Its SY-2101, a novel oral form of arsenic trioxide (ATO) being developed for the treatment of AML. Its SY-5609, is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors.

Webull offers kinds of Syros Pharmaceuticals Inc stock information, including NASDAQ:SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.